PSYC Continues to See Strong Value Potential Tied to Its Investment in The Conscious Fund
February 02 2022 - 8:30AM
InvestorsHub NewsWire
PSYC Continues
to See Strong Value Potential Tied to Its Investment in The
Conscious Fund
LAKE OSWEGO,OR
-- February 2, 2022 -- InvestorsHub NewsWire -- Global Trac Solutions,
Inc. (OTCPink:
PSYC) (“Global” “PSYC” or the “Company”)
a
media leader for the emerging medicinal psychedelics sector, and
authorities behind Psychedelic Spotlight, a top ranking psychedelic news
and information platform, is pleased to
provide an update on the Company’s investment position
with The Conscious Fund
(“TCF”), a leading investment fund focused on
early-stage ventures in the emerging psychedelic medicine
sector.
In January of 2021, PSYC earned
its position as a stakeholder in TCF’s impressive portfolio of
evolving psychedelic-focused companies by way of its completion of
a $125,000 USD investment in TCF’s private placement
memorandum.
Though it maintains there can be
no assurances, the Company states that this investment was intended
to diversify its positioning within the burgeoning medicinal
psychedelic space and present PSYC with the potential to earn a
positive return on its investment based on the anticipated success
it believes many of the companies within TCF’s portfolio may
achieve over the next several years.
Over the past 12 months, a solid
number of the TCF’s portfolio companies have made encouraging
progress in their development which, pursuant to the Company, lends
to its optimistic outlook in the stake it has in the
portfolio.
The Company believes that the
following highlights are effective demonstrations of this
progress:
- Albert Labs is closing $4M in its
Series A ahead of its listing on the CSE and is targeting late 2022
to begin treating patients with cancer related anxiety through
psilocybin therapy
- Wesana Health recently announced
that it has received approval from the FDA granting Wesana’s request for a pre-IND
(Investigational New Drug) meeting to discuss the novel therapy and
proprietary protocol of SANA-013 for the treatment of Traumatic
Brain Injury (TBI) related major depressive disorder
(MDD)
- Enveric Biosciences (f/k/a
MagicMed Industries) raised $25M, uplisted to the NASDAQ, and
recently filed 15 patent applications with claims directed to
millions of individual molecules
- Cybin became the first
psychedelic-focused company to list on the NYSE and continues to
make tremendous progress with its novel psychedelic compounds that
are targeting disorders such as depression and
alcoholism
- Numinus Wellness recently
completed its up listing to the OTCQX and also announced in January
that its research facility – Numinus
Bioscience – has been included on Health Canada’s list of federally
licensed psilocybin producers
“In just a years’ time since
completing our initial investment with TCF, we have watched the
value potential associated with their portfolio, and our
investment, increase tremendously based on the exciting progress
many of these companies have made in the last several months,” said
PSYC CEO, David Flores.
“Acquiring a stake in TCF was
always intended to be a strategic move on our part to help
strengthen shareholder value by creating an element of
diversification to PSYC’s holdings. And
while the actual long-term success associated with any of the
companies within TCF’s portfolio cannot be guaranteed, we firmly
believe that many of them are demonstrating the very real
capability of becoming next-generation leaders for this emerging
sector of psychedelic medicine. Therefore, it is hard for us to not
be encouraged by the value return potential we continue to see in
our stake in TCF and we are eager to see what exciting developments
are in store for many of these companies throughout 2022.”
About Global Trac Solutions, Inc.
(OTCPink: PSYC)
At Global Trac Solutions we are
integrating media, creativity, and technology to develop and deploy
thought-provoking ideas and solutions that are fostering and
transforming the approach to some of society’s most pressing
matters.
PSYC has expressed its intent and
commitment to positioning itself at the forefront of the
psychedelic revolution and as a resource center for discovering and
understanding the latest research and business opportunities
surrounding psychedelic inspired medicines. In conjunction with the
FDA’s more open-minded approach to psychedelic medicines, and as
several major U.S. cities continue to approve the decriminalization
of psilocybin, we believe investors are speculating that the
psychedelic boom could be bigger than that of cannabis. PSYC is
your source for current investment related news specific to
psychedelic medicines and cutting-edge research improving overall
health, moving this sector into the mainstream.
We are dedicated to a
forward-thinking approach that embraces groundbreaking new
technology and innovations and through the vision of business
development we intend to continue to evolve into these unchartered
territories as the industry leaders of the future. We contend that
we are truly the right TRAC to follow.
Forward-Looking Statements
Disclaimer:
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. In some cases, you can
identify forward-looking statements by the following words:
"anticipate," "believe," "continue," "could," "estimate," "expect,"
"intend," "may," "ongoing," "plan," "potential," "predict,"
"project," "should," "will," "would," or the negative of these
terms or other comparable terminology, although not all
forward-looking statements contain these words. Forward-looking
statements are not a guarantee of future performance or results and
will not necessarily be accurate indications of the times at, or
by, which such performance or results will be achieved.
Forward-looking statements are based on information available at
the time the statements are made and involve known and unknown
risks, uncertainty and other factors, including the effect of
COVID-19 and the success of the current vaccine distribution, that
may cause our results, levels of activity, performance or
achievements to be materially different from the information
expressed or implied by the forward-looking statements in this
press release. This press release should be considered in light of
all filings of the Company that are disclosed on the OTC
Markets.com website.
Disclaimer: Global Trac
Solutions, Inc. does not in any way encourage or condone the use,
purchase, sale or transfer of any illegal substances, nor do we
encourage or condone partaking in any unlawful activities. We
support a harm reduction approach for the purpose of education and
promoting individual and public safety. If you are choosing to use
psychedelic substances, please do so
responsibly.
Corporate
Contact:
Global Trac Solutions, Inc.
(PSYC)
www.globaltracsolutions.com
(702) 239-1919
psyc@globaltracsolutions.com
OTCPINK: PSYC
PSYC (PK) (USOTC:PSYC)
Historical Stock Chart
From Mar 2024 to Apr 2024
PSYC (PK) (USOTC:PSYC)
Historical Stock Chart
From Apr 2023 to Apr 2024